Purported Benefits, Side Effects & More


Purported Benefits, Side Effects & More

For Patients & Caregivers

Tell your healthcare providers about any dietary supplements you’re taking, such as herbs, vitamins, minerals, and natural or home remedies. This will help them manage your care and keep you safe.

What is it?

Probiotics are made of good bacteria and yeast. The good bacteria helps to fight off issues caused by bad bacteria, such as problems with digestion and bowel function. Taking probiotics helps balance out the bacteria in your stomach and can help you feel better.

Probiotics are found in many foods and drinks like yogurt, kefir, miso, and sauerkraut, and cottage cheese. You can also take probiotics as a dietary supplement in many forms that include:

  • Capsules
  • Pills
  • Powders
  • Liquids
What are the potential uses and benefits?

 Probiotics are used to help:

  • Prevent and treat diarrhea (loose or watery bowel movements).
  • Treat inflammatory bowel disease (swelling in your digestive tract).
  • Prevent gastroenteritis (stomach flu with symptoms including diarrhea, cramps, nausea, vomiting, and fever).
  • Reduce symptoms of irritable bowel syndrome (IBS) (an intestinal disorder that causes pain in the belly, gas, diarrhea, and constipation).
  • Reduce side effects caused by cancer treatment such as diarrhea and stomach pain.
  • Treat urinary tract infections (UTIs)

Probiotics also have other uses that haven’t been studied by doctors to see if they work.

It’s generally safe to have foods and drinks with probiotics in them. However, talk with your healthcare providers before taking probiotics as supplements.

For more information, read the “What else do I need to know?” section below.

What else do I need to know?
  • Talk to your healthcare provider before taking probiotics as a dietary supplement if you have a weakened immune system because of your cancer treatment. Some probiotics may cause harm.
  • Talk to your healthcare provider before taking probiotics as a dietary supplement if you have a central venous catheter (CVC), such as an implanted port. Some probiotics may cause harm.
  • Babies who are underweight, have umbilical catheters, or have low oxygen levels should not be given probiotics as they can cause harm.

For Healthcare Professionals

Clinical Summary

The term “Probiotic” (Greek for “prolife”) came into being in the 1960s to define substances produced by protozoa, which support the growth of other microorganisms (1). Following revisions over the years, probiotics are currently defined by the Food and Agriculture Organization of the World Health Organization as “live microorganisms, which when consumed in adequate amounts, confer a health effect on the host” (2). Most probiotics consist of lactic-acid producing, non-virulent bacteria, such as Lactobacillus, Streptococcus, Bifidobacterium, Propionibacterium and Enterococcus or non-pathogenic yeasts such as Saccharomyces boulardii. Probiotics have gained immense popularity over the last two decades for their perceived health benefits which include improved digestion, immune function and nutrient absorption but the most important being the reversal of dysbiosis (changes in the function or composition of gut microbes or “microbiota”) that is hypothesized to play a role in the development of several chronic and degenerative diseases (3).

Although gut microbiota is known to develop at birth, nutrition, lifestyle, and changes in the host genome during later years can shift its makeup and activity, which in turn influences overall health and the risk of developing disease. Antibiotic use has also been associated with gut microbiota disruption in general population, increasing the risk of chronic disease (77); in patients undergoing allogeneic hematopoietic cell transplantation (4), with the greatest shifts occuring between stem cell infusion and reconstitution of healthy immune cells (75); as well as in allogeneic bone marrow transplantation patients (5). Furthermore, antibiotics were found to inhibit the benefits of immune checkpoint-inhibitors in patients with advanced cancer (78); and patients who were administered antibiotics before, and not during, immune checkpoint-inhibitor therapy had worse treatment response and overall survival  (79). Research is underway to determine strategies for modulating the gut microbiome to improve immune response in cancer.

Probiotic supplements are currently promoted for the prevention and treatment of inflammatory bowel disease, gastroenteritis, irritable bowel syndrome, allergies, dental cavities, and for managing diarrhea induced by antibiotics, by the bacterium Clostridium difficile (C. difficile), and that associated with chemotherapy (64).

The strongest evidence of effectiveness of probiotics is for acute infectious diarrhea (7). Supplementation also was shown useful in alleviating antibiotic-associated diarrhea (8). Although RCTs did not find benefit for managing C. difficile-associated diarrhea (9), data suggest effectiveness in preventing C. difficile infection (63) (93) and for pouchitis (inflammation of the ileal pouch in post-colectomy patients). Interestingly, even though a range of products were shown useful in treating and sustaining remissions of mild to moderately active ulcerative colitis, findings on Crohn’s disease are not promising (65). Based on the association of intestinal bacteria with symptoms of irritable bowel syndrome (IBS), supplementation has been explored in a few studies with promising findings but well-designed trials are lacking (11). In a study of patients with systemic sclerosis, probiotics did not improve gastrointestinal symptoms (67).
Analyses of the National Health and Nutrition survey results revealed consumption of yogurt or probiotics reduces the risk of proteinuric kidney disease (12), but definitive conclusions of benefit against urinary tract infections (13) or bacterial vaginosis (60) are lacking. Probiotic use was also shown to increase resistance to risk factors associated with dental caries in an RCT (14), and to improve memory impairment in a murine model (15). Probiotics conferred a moderate benefit for eczema prevention but not for other allergic conditions (16). Supplementation also reduced glycemic and inflammatory markers in patients with non-alcoholic fatty liver disease (58). But evidence to support its role in managing cystic fibrosis is lacking (61). In other studies, supplementation did not prevent influenza in women healthcare workers (82), nor bacterial vaginosis in pregnant women (83), but shortened the healing time in patients with lactational breast abscesses  (94).

As increasing evidence indicates that gut bacteria are important determinants of metabolic disorders, probiotics are being investigated as a possible therapeutic option. Thus far, benefits were reported against obesity and diabetes (17). Meta analyses suggest that supplementation helps reduce periodontal parameters and halitosis associated with severe periodontitis (68), helps prevent oral candidiasis in the elderly (62), may lower fasting blood glucose level in adults (59) and improve lipid metabolism by lowering the levels of LDL and total cholesterol (18).

Another important application of probiotic therapy is in pediatrics for the treatment of gastrointestinal disorders and allergies. Meta analyses indicate enteral supplementation is effective in preventing severe necrotizing enterocolitis in preterm infants  (19). A significant reduction in acute diarrhea was also reported in children, independent of the bacterial strains employed (7) (69). Additional studies showed efficacy of probiotics against antibiotic-associated diarrhea (20) (95) and for lowering the incidence of eczema in late infancy (70). But available evidence does not support use for allergic diseases (21), and data are insufficient to assess effects in children with short bowel syndrome, a malabsorption disorder (22).

Preliminary studies indicate that probiotics may also have anti-carcinogenic potential. Oral administration of Lactobacillus casei BL23 had a protective effect against dimethyl hydrazine-induced colorectal cancer (23), and a probiotic mixture attenuated the growth of hepatocellular carcinoma (24). A murine melanoma model suggests that manipulating microbiota may modulate cancer immunotherapy by enhancing antitumor immunity through administering a Bifidobacterium strain (71). Gut microbiome may also modulate responses to anti PD-1 immunotherapy in melanoma patients (80). Epidemiological data suggest an association between consumption of non-pasteurized dairy products and lower incidence of colorectal cancer (25). Probiotics may also aid in controlling symptoms associated with cancer treatments: Systematic reviews found supplementation to affect reductions in the severity and frequency of treatment-associated diarrhea, and the need for anti-diarrheal medication in cancer patients (26); and to promote recovery of gastrointestinal function following gastrointestinal cancer surgery  (89) and craniotomy (96); In colorectal cancer patients, perioperative probiotic treatment reduced surgical site infections (27), improved bowel function (28), and a systematic review concluded that probiotics/synbiotics help modulate enteric microbiota, improve postoperative outcomes, gut barrier function and reduce inflammatory parameters (86). Probiotics may also help prevent chemo-related cognitive impairment in breast cancer patients  (90); decrease severity of chemo- and radiotherapy-induced oral mucositis in patients with nasopharyngeal carcinoma (87); and reduce oral Candida following radiotherapy in patients with head and neck cancer  (88), although supplementation was ineffective in preventing radiation-induced mucositis (72). A systematic review evaluating probiotics in oncological surgery found substantial risk of bias across majority of the studies analyzed, warranting the need for well-designed studies  (91).

Additional strategies used to modulate gut microbiota include “prebiotics” and “fecal microbiota transplantation” (FMT). Prebiotics or functional foods are non-digestible food ingredients that benefit the host by selectively promoting growth or activity of helpful gut bacteria. Currently used prebiotics include the fructans inulin and fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), and lactulose. Data on prebiotics for IBS are conflicting (11). Because probiotics are short-lived, prebiotics are being co-administered to maintain their levels in the gut, and this combination is called “synbiotic therapy”. It was reported useful in controlling symptoms associated with IBS (30); and may also benefit gut functioning in healthy community-dwelling elders (84).
FMT involves administration of fecal matter from a healthy donor into a recipient by enema, colonoscopy or through the upper gastrointestinal tract in the form of oral capsules, via nasogastric, nasoduodenal or nasoenteric tube, or by endoscopy, to restore normal gut flora. FMT may benefit IBS patients although the quality of evidence is low (31). In oncology settings, FMT was found effective against immune checkpoint inhibitor (ICI)-associated colitis (81); and autologous fecal microbiota transplantation (auto-FMT), for reestablishing intestinal microbiota composition in patients with gut microbiota depletion due to antibiotic treatment during allogeneic hematopoietic stem cell transplantation (76). A synbiotic mouthwash was effective in reducing and preventing oral mucositis intensity in oral cancer patients undergoing radiotherapy (97). Synbiotic supplements also reduced chemo-induced diarrhea in children with acute lymphoblastic leukemia (98).

In summary, available data suggest probiotics may improve certain health outcomes by inducing favorable changes in the intestinal bacteria. But the overall evidence to support their use is limited due to small sample size, poor methodology, variation in the species and strains of bacteria, and in the dosage and duration of administration. Variation in the response to probiotics is also an important factor to consider because genes that respond to probiotic intake were shown to be strain-specific (32) and to cluster according to the individual and not by intervention (32) (33). Furthermore, gut colonization is not always achieved despite supplementation with probiotics (73). In another study that examined post-antibiotic recovery in humans, administration of probiotics was associated with a delay in gut-microbiome reconstitution (74). Well-designed studies and specific recommendations are needed to establish probiotic use for different age groups and disorders, and to determine long-term safety.

Of note, early observational data suggest that indiscriminate use of commercially available probiotics may be harmful in the setting of immune checkpoint blockade treatment in cancer patients (92).

Food Sources

Yogurt, miso, tempeh, kefir, pickled vegetables, sauerkraut, kimchi and buttermilk

Purported Uses and Benefits
  • Diarrhea
  • Inflammatory bowel disease
  • Gastroenteritis
  • Irritable bowel syndrome
  • Cancer treatment-associated side effects
  • Urinary tract infections
Mechanism of Action

Proposed mechanisms by which probiotics influence colonization in the gut include production of inhibitory compounds to suppress the growth of pathogenic microorganisms, and production of substrates to promote the growth of beneficial bacteria. Probiotics can also indirectly influence shifts in microbiota by interacting with the mucosal system, which affects systemic immunity; and by reducing pro-inflammatory markers implicated in many disorders (34) (35).

Studies using murine models indicate that administration of S. boulardii to type-2 diabetic and obese mice resulted in reduced inflammation, body weight, fat mass, and hepatic steatosis, along with decreased bacterial population that has been previously associated with obesity and type-2 diabetes (36). Probiotic treatment also affected a reduction in food intake and an improvement in glucose tolerance via release of the hormone glucagon-like protein-1 (GLP-1), a physiological regulator of appetite and food intake (37).

Immunomodulation is one of the ways in which probiotics are thought to influence host health. A subspecies of Bifidobacterium longum prevented Salmonella-associated infection in mice by inducing T-regulatory cells and by attenuating the activation of nuclear factor-kappa B, which plays a role in the expression of pro-inflammatory genes (38). Induction of T-regulatory cells was also shown in humans along with a reduction in pro-inflammatory biomarkers (39). In addition probiotic administration was shown to reduce pain perception, and to induce changes in the colonic expression of genes that mediate pain and inflammation (40). And a probiotic mixture reduced the growth of hepatocellular carcinoma by shifting the gut microbes toward beneficial bacteria, which produce anti-inflammatory metabolites (24). Protective effects of probiotics were also reported in a murine model of mammary carcinogenesis. Oral administration of a supplement containing Lactobacillus reuteri resulted in inhibition of mammary tumor formation by triggering CD4+/CD25+ lymphocytes, which play a critical role in controlling immune responses (41). Because intestinal bacteria have been shown to influence carcinogenesis and response to anticancer therapy, manipulating them selectively may be a potential strategy to enhance the efficacy of anticancer treatments (66).

  • Patients who are immunocompromised, or have a central venous catheter or critically ill should not take probiotics containing S. boulardii (42).
  • Probiotics should not be given to newborns with very low birth weight, clinical instability, umbilical catheters, and to those with congenital abnormalities or stage III asphyxia (43).
Adverse Reactions

Pediatric Case Reports:

  • Bacteremia associated with Escherichia coli and Bifidobacterium species: In pre-term infants (44) (45) (46) as well as a newborn (47) following probiotic therapy.
  • Probiotic-associated L. rhamnosus pneumonia: In a 11-month-old baby, secondary to a respiratory viral infection. She recovered after antibiotic therapy (49).
  • D-lactic acid encephalopathy, involving intermittent ataxia: In a 5-year-old girl following use of probiotics to control diarrhea. She was treated with oral antibiotics (50).
  • Bacteremia associated with Lactobacillus: In a 17-year-old boy with ulcerative colitis. His symptoms, which included fever, flushing and chills resolved following treatment with antibiotics (48).

Adult Case Reports:

  • Fungemia involving Saccharomyces cerevisiae: In a patient with Clostridium difficile-associated diarrhea who was treated orally with the probiotic yeast Saccharomyces boulardii (51).
  • Sepsis associated with Saccharomyces cervesiae: In a 34-year-old woman with extensive burns, and administered Saccharomyces boulardii to improve the digestive tolerance to enteral feeding (52).
  • Fungemia: In a 79-year-old woman following treatment with Sacchaflor (a probiotic consisting of S. boulardii) for Clostridium difficile-associated diarrhea. Her symptoms improved after discontinuing use of Sacchaflor (53).
  • Lactobacillus empyema: In a 54-year-old HIV-infected lung transplant patient, after taking a probiotic containing Lactobacillus rhamnosus GG. His symptoms resolved with antibiotic treatment (6).
  • Lactobacillus acidophilus bacteremia: In a patient with AIDS and Hodgkin’s disease following probiotic therapy containing L. acidophilus  (54).
  • Sepsis due to preoperative administration of a probiotic containing Lactobacillus rhamnosus: In a 24-year-old woman following an aortic valve replacement. She was treated with antibiotics  (55).
  • Bloodstream infection: In a critically ill 64-year-old patient with acute pancreatitis, following administration of a symbiotic formula containing Pediococcus pentosaceus. He was treated with antibiotics (56).
  • Accidental septicemia: In a 25-year-old man, following intravenous administration of a probiotic containing Bacillus clausii. He recovered after a 5-month course of combined antibiotics (85).
  • Lactobacillus rhamnosus sepsis, endocarditis and septic emboli: In a patient with ulcerative colitis, treated with lactobacillus-containing probiotics. His symptoms necessitated intravenous antibiotics followed by indefinite amoxicillin suppressive therapy (99).
  • Bacteremia due to Lacticaseibacillus rhamnosus: In two patients in intensive care units, associated with the use of a probiotic product (100).


Herb-Drug Interactions
  • Hepatic drug-metabolizing enzymes: In mice, administration of VSL3, a probiotic mixture of 8 bacterial strains, was shown to modify the expression of Cyp4v3, alcohol dehydrogenase 1, carboxyesterase 2a, and multiple phase II glutathione-S-transferases (57). Human data are lacking.
  1. Lilly DM, Stillwell RH. PROBIOTICS: GROWTH-PROMOTING FACTORS PRODUCED BY MICROORGANISMS. Science. Feb 12 1965;147(3659):747-748.
  2. FAO. Joint FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food. 2002. Accessed May 11, 2020.
  3. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. Jun 8 2012;336(6086):1262-1267.
  4. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. Oct 2012;55(7):905-914.
  5. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. May 7 2012;209(5):903-911.
  6. Luong ML, Sareyyupoglu B, Nguyen MH, et al. Lactobacillus probiotic use in cardiothoracic transplant recipients: a link to invasive Lactobacillus infection? Transpl Infect Dis. Dec 2010;12(6):561-564.
  7. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. Jun 2006;6(6):374-382.
  8. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. May 9 2012;307(18):1959-1969.
  9. Crow JR, Davis SL, Chaykosky DM, Smith TT, Smith JM. Probiotics and Fecal Microbiota Transplant for Primary and Secondary Prevention of Clostridium difficile Infection. Pharmacotherapy. Nov 2015;35(11):1016-1025.
  10. Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr. Mar 2010;91(3):687-703.
  11. Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol. Feb 21 2016;22(7):2219-2241.
  12. Yacoub R, Kaji D, Patel SN, et al. Association between probiotic and yogurt consumption and kidney disease: insights from NHANES. Nutr J. 2016;15(1):10.
  13. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015;12:CD008772.
  14. Nishihara T, Suzuki N, Yoneda M, Hirofuji T. Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial. BMC Oral Health. 2014;14:110.
  15. Woo JY, Gu W, Kim KA, Jang SE, Han MJ, Kim DH. Lactobacillus pentosus var. plantarum C29 ameliorates memory impairment and inflammaging in a D-galactose-induced accelerated aging mouse model. Anaerobe. Jun 2014;27:22-26.
  16. West CE, Jenmalm MC, Kozyrskyj AL, Prescott SL. Probiotics for treatment and primary prevention of allergic diseases and asthma: looking back and moving forward. Expert Rev Clin Immunol. Jan 28 2016.
  17. Le Barz M, Anhe FF, Varin TV, et al. Probiotics as Complementary Treatment for Metabolic Disorders. Diabetes Metab J. Aug 2015;39(4):291-303.
  18. Cho YA, Kim J. Effect of Probiotics on Blood Lipid Concentrations: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). Oct 2015;94(43):e1714.
  19. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid Based Child Health. Sep 2014;9(3):584-671.
  20. Szajewska H, Canani RB, Guarino A, et al. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. Mar 2016;62(3):495-506.
  21. Fiocchi A, Pawankar R, Cuello-Garcia C, et al. World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. World Allergy Organ J. 2015;8(1):4.
  22. Reddy VS, Patole SK, Rao S. Role of probiotics in short bowel syndrome in infants and children—a systematic review. Nutrients. Mar 2013;5(3):679-699.
  23. Lenoir M, Del Carmen S, Cortes-Perez NG, et al. Lactobacillus casei BL23 regulates T and Th17 T-cell populations and reduces DMH-associated colorectal cancer. J Gastroenterol. Jan 9 2016.
  24. Li J, Sung CY, Lee N, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A. Feb 16 2016.
  25. Campbell TC. A study on diet, nutrition and disease in the People’s Republic of China. Part I. Bol Asoc Med P R. Mar 1990;82(3):132-134.
  26. Redman MG, Ward EJ, Phillips RS. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol. Oct 2014;25(10):1919-1929.
  27. Aisu N, Tanimura S, Yamashita Y, et al. Impact of perioperative probiotic treatment for surgical site infections in patients with colorectal cancer. Exp Ther Med. Sep 2015;10(3):966-972.
  28. Yang Y, Xia Y, Chen H, et al. The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial. Oncotarget. Jan 27 2016.
  29. Probiotics and Cancer. Accessed May 11, 2020.
  30. Bittner AC, Croffut RM, Stranahan MC. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study.Clin Ther. Jun 2005;27(6):755-761.
  31. Bowman KA, Broussard EK, Surawicz CM. Fecal microbiota transplantation: current clinical efficacy and future prospects. Clin Exp Gastroenterol. 2015;8:285-291.
  32. van Baarlen P, Troost F, van der Meer C, et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci U S A. Mar 15 2011;108 Suppl 1:4562-4569.
  33. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol. Jan 2012;10(1):66-78.
  34. Sanders ME. Impact of probiotics on colonizing microbiota of the gut. J Clin Gastroenterol. Nov 2011;45 Suppl:S115-119.
  35. Thomas LV, Suzuki K, Zhao J. Probiotics: a proactive approach to health. A symposium report. Br J Nutr. Dec 2015;114 Suppl 1:S1-15.
  36. Everard A, Matamoros S, Geurts L, Delzenne NM, Cani PD. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. MBio. 2014;5(3):e01011-01014.
  37. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. Aug 30 2013;288(35):25088-25097.
  38. O’Mahony C, Scully P, O’Mahony D, et al. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 2008;4(8):e1000112.
  39. Groeger D, O’Mahony L, Murphy EF, et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. Jul-Aug 2013;4(4):325-339.
  40. Distrutti E, Cipriani S, Mencarelli A, Renga B, Fiorucci S. Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS One. 2013;8(5):e63893.
  41. Lakritz JR, Poutahidis T, Levkovich T, et al. Beneficial bacteria stimulate host immune cells to counteract dietary and genetic predisposition to mammary cancer in mice.Int J Cancer. Aug 1 2014;135(3):529-540.
  42. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. May 2010;31(5):431-455.
  43. Parker R. Probiotic guideline for necrotizing enterocolitis prevention in very low-birth-weight neonates. Adv Neonatal Care. Apr 2014;14(2):88-95.
  44. Guenther K, Straube E, Pfister W, Guenther A, Huebler A. Sever sepsis after probiotic treatment with Escherichia coli NISSLE 1917. Pediatr Infect Dis J. Feb 2010;29(2):188-189.
  45. Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis. Mar 15 2015;60(6):924-927.
  46. Jenke A, Ruf EM, Hoppe T, Heldmann M, Wirth S. Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy. Arch Dis Child Fetal Neonatal Ed. May 2012;97(3):F217-218.
  47. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr. Apr 2010;156(4):679-681.
  48. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. May-Jun 2013;47(5):437-439.
  49. Doern CD, Nguyen ST, Afolabi F, Burnham CA. Probiotic-associated aspiration pneumonia due to Lactobacillus rhamnosus. J Clin Microbiol. Aug 2014;52(8):3124-3126.
  50. Munakata S, Arakawa C, Kohira R, Fujita Y, Fuchigami T, Mugishima H. A case of D-lactic acid encephalopathy associated with use of probiotics. Brain Dev. Sep 2010;32(8):691-694.
  51. Santino I, Alari A, Bono S, et al. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int J Immunopathol Pharmacol. Jan-Mar 2014;27(1):143-146.
  52. Stefanatou E, Kompoti M, Paridou A, et al. Probiotic sepsis due to Saccharomyces fungaemia in a critically ill burn patient. Mycoses. Sep 2011;54(5):e643-646.
  53. Thygesen JB, Glerup H, Tarp B. Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Rep. 2012;2012.
  54. Ledoux D, Labombardi VJ, Karter D. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin’s disease. Int J STD AIDS. Apr 2006;17(4):280-282.
  55. Kochan P, Chmielarczyk A, Szymaniak L, et al. Lactobacillus rhamnosus administration causes sepsis in a cardiosurgical patient—is the time right to revise probiotic safety guidelines? Clin Microbiol Infect. Oct 2011;17(10):1589-1592.
  56. Papanikolaou MN, Balla M, Papavasilopoulou T, Kofinas G, Karatzas S. Probiotics: an obedient ally or an insidious enemy? Crit Care. 2012;16(6):456.
  57. Selwyn FP, Cheng SL, Klaassen CD, Cui JY. Regulation of Hepatic Drug-Metabolizing Enzymes in Germ-Free Mice by Conventionalization and Probiotics. Drug Metab Dispos. Feb 2016;44(2):262-274.
  58. Sepideh A, Karim P, Hossein A, et al. Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial. J Am Coll Nutr.2016 Aug;35(6):500-505.
  59. Nikbakht E, Khalesi S, Singh I, Williams LT, West NP, Colson N.Effect of probiotics and synbiotics on blood glucose: a systematic review and meta-analysis of controlled trials. Eur J Nutr. 2016 Sep 3. [Epub ahead of print]
  60. Tan H, Fu Y, Yang C, Ma J. Effects of metronidazole combined probiotics over metronidazole alone for the treatment of bacterial vaginosis: a meta-analysis of randomized clinical trials. Arch Gynecol Obstet. 2017 Jun;295(6):1331-1339.
  61. Nikniaz Z, Nikniaz L, Bilan N, Somi MH, Faramarzi E. Does probiotic supplementation affect pulmonary exacerbation and intestinal inflammation in cystic fibrosis: a systematic review of randomized clinical trials. World J Pediatr. 2017 Apr 29. doi: 10.1007/s12519-017-0033-6. [Epub ahead of print]
  62. Ai R, Wei J, Ma D, Jiang L, Dan H, Zhou Y, Ji N, Zeng X, Chen Q. A meta-analysis of randomized trials assessing the effects of probiotic preparations on oral candidiasis in the elderly. Arch Oral Biol. 2017 Apr 30;83:187-192.
  63. Johnston BC, Lytvyn L, Lo CK et al. Microbial Preparations (Probiotics) for the Prevention of Clostridium difficile Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants. Infect Control Hosp Epidemiol. 2018 Jul;39(7):771-781.
  64. Vanderhoof JA, Young R. Probiotics in the United States. Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S67-72; discussion S144-51.
  65. Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Aug;46(4):389-400.
  66. Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, Kroemer G. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 2015 Jan 21;7(271):271ps1.
  67. Marighela TF, Arismendi MI, Marvulle V, Brunialti MKC, Salomão R, Kayser C. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial. Rheumatology (Oxford). 2019 May 5. pii: kez160.
  68. Soares LG, Carvalho EB, Tinoco EMB. Clinical effect of Lactobacillus on the treatment of severe periodontitis and halitosis: A double-blinded, placebo-controlled, randomized clinical trial. Am J Dent. 2019 Feb;32(1):9-13.
  69. Sudha MR, Jayanthi N, Pandey DC, Verma AK. Bacillus clausii UBBC-07 reduces severity of diarrhoea in children under 5 years of age: a double blind placebo controlled study. Benef Microbes. 2019 Mar 13;10(2):149-154.
  70. Schmidt RM, Pilmann Laursen R, et al. Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial. Pediatr Allergy Immunol. 2019 May;30(3):335-340.
  71. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27;350(6264):1084-9.
  72. DE Sanctis V, Belgioia L, Cante D, et al. Lactobacillus brevis CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study. Anticancer Res. 2019 Apr;39(4):1935-1942.
  73. Zmora N, Zilberman-Schapira G, Suez J, et al. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell. 2018 Sep 6;174(6):1388-1405.e21.
  74. Suez J, Zmora N, Zilberman-Schapira G, et al. Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell. 2018 Sep 6;174(6):1406-1423.e16.
  75. Morjaria S, Schluter J, Taylor BP, et al. Antibiotic-Induced Shifts in Fecal Microbiota Density and Composition during Hematopoietic Stem Cell Transplantation. Infect Immun. 2019 Aug 21;87(9). pii: e00206-19.
  76. Taur Y, Coyte K, Schluter J, et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med. 2018 Sep 26;10(460). pii: eaap9489.
  77. Wilkins LJ, Monga M, Miller AW. Defining Dysbiosis for a Cluster of Chronic Diseases. Sci Rep. 2019 Sep 9;9(1):12918.
  78. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 5;359(6371):91-97.
  79. Pinato DJ, Howlett S, Ottaviani D, et al. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Oncol. 2019 Sep 12.
  80. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 Jan 5;359(6371):97-103.
  81. Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 Dec;24(12):1804-1808.
  82. Kinoshita T, Maruyama K, Suyama K, et al. The effects of OLL1073R-1 yogurt intake on influenza incidence and immunological markers among women healthcare workers: a randomized controlled trial. Food Funct. 2019 Dec 11;10(12):8129-8136.
  83. Husain S, Allotey J, Drymoussi Z, et al. Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. BJOG. 2020 Jan;127(2):275-284.
  85. Monnerat N, Lambert AC, Genné D. What happens after an accidental intravenous probiotic injection?. Clin Microbiol Infect. 2020;26(4):517‐518.
  86. Wierzbicka A, Mańkowska-Wierzbicka D, Mardas M, Stelmach-Mardas M. Role of Probiotics in Modulating Human Gut Microbiota Populations and Activities in Patients with Colorectal Cancer-A Systematic Review of Clinical Trials. Nutrients. 2021 Apr 1;13(4):1160.
  87. Xia C, Jiang C, Li W, et al. A Phase II Randomized Clinical Trial and Mechanistic Studies Using Improved Probiotics to Prevent Oral Mucositis Induced by Concurrent Radiotherapy and Chemotherapy in Nasopharyngeal Carcinoma. Front Immunol. 2021 Mar 24;12:618150.
  88. Doppalapudi R, Vundavalli S, Prabhat MP. Effect of probiotic bacteria on oral Candida in head- and neck-radiotherapy patients: A randomized clinical trial. J Cancer Res Ther. 2020 Apr-Jun;16(3):470-477.
  89. Tang G, Huang W, Tao J, Wei Z. Prophylactic effects of probiotics or synbiotics on postoperative ileus after gastrointestinal cancer surgery: A meta-analysis of randomized controlled trials. PLoS One. 2022 Mar 1;17(3):e0264759.
  90. Juan Z, Chen J, Ding B, et al. Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial. Eur J Cancer. 2022 Jan;161:10-22.
  91. Cogo E, Elsayed M, Liang V, et al. Probiotics Evaluation in Oncological Surgery: A Systematic Review of 36 Randomized Controlled Trials Assessing 21 Diverse Formulations. Curr Oncol. 2021 Dec 7;28(6):5192-5214.
  92. Spencer CN, McQuade JL, Gopalakrishnan V, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24;374(6575):1632-1640.
  93. Louie T, Golan Y, Khanna S, et al. VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial. JAMA. 2023 Apr 25;329(16):1356-1366.
  94. Zhang Y, Gao Y, Qin J, et al. Breast microecology improvement using probiotics following needle aspiration in patients with lactational breast abscess: a multi-center randomized double-blind controlled trial. Sci Rep. 2022 Oct 6;12(1):16692.
  95. Lukasik J, Dierikx T, Besseling-van der Vaart I, de Meij T, Szajewska H; Multispecies Probiotic in AAD Study Group. Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial. JAMA Pediatr. 2022 Sep 1;176(9):860-866.
  96. Jiang M, Zhang X, Zhang Y, et al. The Effects of Perioperative Probiotics on Postoperative Gastrointestinal Function in Patients with Brain Tumors: A Randomized, Placebo-Controlled Study. Nutr Cancer. 2023;75(4):1132-1142.
  97. Manifar S, Koopaie M, Jahromi ZM, Kolahdooz S. Effect of synbiotic mouthwash on oral mucositis induced by radiotherapy in oral cancer patients: a double-blind randomized clinical trial. Support Care Cancer. 2022 Dec 15;31(1):31.
  98. Eghbali A, Ghaffari K, Khalilpour A, et al. The effects of LactoCare synbiotic administration on chemotherapy-induced nausea, vomiting, diarrhea, and constipation in children with ALL: A double-blind randomized clinical trial. Pediatr Blood Cancer. 2023 Jun;70(6):e30328.
  99. Karime C, Barrios MS, Wiest NE, Stancampiano F. Lactobacillus rhamnosus sepsis, endocarditis and septic emboli in a patient with ulcerative colitis taking probiotics. BMJ Case Rep. 2022 Jun 28;15(6):e249020.
  100. Mikucka A, Deptuła A, Bogiel T, et al. Bacteraemia Caused by Probiotic Strains of Lacticaseibacillus rhamnosus-Case Studies Highlighting the Need for Careful Thought before Using Microbes for Health Benefits. Pathogens. 2022 Aug 26;11(9):977.
Email your questions and comments to [email protected].

Last Updated